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Heme oxygenases (HO) are rate-limiting enzymes that cat-
alyze the conversion of heme into carbon monoxide and
biliverdin (1). They consist of two different isoforms, HO-
1 and HO-2. They have antioxidant capacity and therefore
act as potent anti-inflammatory proteins whenever oxida-
tive injury takes place. HO-2 is constitutively produced
within the brain and testes, whereas HO-1 is produced
ubiquitously, but only marginally in the resting state (2).
Rapid induction of HO-1 follows various stresses (3, 4).
Recent studies have suggested protective roles of HO-1 in
various inflammatory conditions (5). However, no human
disease has so far been attributed to primary deficiency of
HO-1. We describe a six-year-old boy with HO-1 deficien-
cy. The patient has been suffering marked growth retar-
dation and developmental delay associated with erythro-
cyte fragmentation and persistent intravascular
hemolysis. Marked abnormality of coagulation/fibrinol-
ysis system, paradoxical increase of haptoglobin concen-
tration, and low level of serum bilirubin were intriguing
findings in this patient. Low serum bilirubin concentra-
tion in the presence of continuing hemolysis led us to sus-
pect an abnormality in the hemoglobin metabolic path-
way, and we wondered if any defect in HO activity was
present in this patient. Immunoblotting analysis of
Epstein-Barr virus–transformed lymphoblastoid cell line
(LCL) clearly showed that he has complete deficiency of
HO-1 production after stimulation by stress-inducing fac-
tors. Mutational analysis revealed abnormalities in both
alleles. Complete deletion of exon2 was found in the
maternal allele, and a 2 nucleotide deletion was present
within exon3 of the paternal allele. The combination of
these two mutations in the patient resulted in the failure
of production of functional HO-1 protein. Lack of this
important enzyme may explain the wide variety of clinical
symptoms and laboratory findings noted.
Methods
Case presentation. The patient was 26 months old when he first
sought medical advice at a hospital because of recurrent fever and
generalized erythematous rash. His brother and sister were
healthy. The mother had experienced two intrauterine fetal
deaths. Growth retardation was apparent and marked
hepatomegaly was noted, but the spleen was impalpable. Asple-
nia was confirmed by abdominal ultrasonography and isotope
image scanning. Hematuria and proteinuria were con-
stantly present. The white cell count was 51,600/m l (nor-
mal 3,300–8,800). Platelet count was 2,260,000/m l (nor-
mal 130,000–350,000). Microcytic, hypochromic anemia was
marked with erythrocyte count 1.48 · 106/m l (normal 4.30–5.50)
and hemoglobin concentration 4.9 g/dl (normal 13.5–17.0).
Serum iron concentration was 64 m g/dl (normal 50–170). Lactate
dehydrogenase was 17,470 IU/L (normal 196–355). Aspartate
aminotransferase was markedly elevated at 442 IU/l (normal
9–42), but alanine aminotransferase was within normal limits.
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The first known human case of heme oxygenase-1 (HO-1) deficiency is presented in this report. The
patient is a six-year-old boy with severe growth retardation. He has been suffering from persistent
hemolytic anemia characterized by marked erythrocyte fragmentation and intravascular hemolysis, with
paradoxical increase of serum haptoglobin and low bilirubin. An abnormal coagulation/fibrinolysis
system, associated with elevated thrombomodulin and von Willebrand factor, indicated the presence
of severe, persistent endothelial damage. Electron microscopy of renal glomeruli revealed detachment
of endothelium, with subendothelial deposition of an unidentified material. Iron deposition was noted
in renal and hepatic tissue. Immunohistochemistry of hepatic tissue and immunoblotting of a cadmi-
um-stimulated Epstein-Barr virus–transformed lymphoblastoid cell line (LCL) revealed complete
absence of HO-1 production. An LCL derived from the patient was extremely sensitive to hemin-induced
cell injury. Sequence analysis of the patient’s HO-1 gene revealed complete loss of exon-2 of the mater-
nal allele and a two-nucleotide deletion within exon3 of the paternal allele. Growth retardation, ane-
mia, iron deposition, and vulnerability to stressful injury are all characteristics observed in recently
described HO–1 targeted mice. This study presents not only the first human case of HO-1 deficiency
but may also provide clues to the key roles played by this important enzyme in vivo.
J. Clin. Invest. 103:129–135 (1999).
Ferritin was 780 ng/ml (normal 26–280). Marked abnormalities
of the coagulation fibrinolysis system were noted. Fibrinogen
was 109 mg/dl (normal, 196–356), fibrin degradation product
was 300.1 m g/ml (normal <5), d-dimer was 186.1 m g/ml (normal
<2.5), thrombin-antithrombin complex was 202.2 m g/l (normal
<3), and plasmin-a 2 plasmin inhibitor complex was 22.3 m g/ml
(normal <0.8). Thrombomodulin was 12 ng/ml (normal <3.5)
and Von Willebrand factor was 580% (normal 60–170). Hyper-
lipidemia was another prominent finding. Triglyceride was 638
mg/dl (normal 32–115) and total cholesterol was 552 mg/dl
(normal 132–220). low-density lipoprotein (LDL) cholesterol was
predominant. Total bilirubin levels were, on the contrary, con-
stantly low at 0.1–0.3 mg/dl (normal 0.2–1.3). Serum haptoglo-
bin concentration was 878 mg/dl (normal 30–252). Hemopexin
was undetectable by immunoelectrophoresis. Serum heme con-
centration was extremely high at 490 m M (normally not
detectable or <1 m M). Repeated direct and indirect Coombs’ tests
were always negative. Serum concentration of interleukin (IL)-6
was 4 pg/ml, tumor necrosis factor-a was <5 pg/ml, IL-2 was 0.8
U/ml, and interferon- g was <0.1 IU/ml. Kidney biopsy revealed
mild mesangial proliferation and endothelial detachment from
the glomerular basement membrane. Liver biopsy showed mild
inflammatory changes with minimal lymphocyte infiltration.
Rudimentary splenic tissue was found on this occasion, but no
histopathological confirmation was done. He has been on oral
steroid and various nonsteroidal anti-inflammatory medications
since he was referred to our hospital 3 years ago. The patient is
now 6 years old and still requires regular transfusions of ery-
throcytes because of progressive hemolytic anemia.
Iron staining of the liver and the kidney biopsy specimen. Paraffin-
embedded liver and kidney sections from the patient were
dewaxed and rehydrated. Prussian-blue staining was performed
to detect ferric iron deposition within the tissue.
Cell preparation. Peripheral blood mononuclear cells (PBMC)
were isolated from the patient and three normal controls. LCLs
were prepared by transforming lymphocytes from normal con-
trols and the patient using supernatant from B95-8. LCL from
the patient was further cloned by a limiting dilution method (6).
Immunohistochemistry of HO-1–producing cells. Paraffin-embed-
ded liver sections from the patient and a normal control were
dewaxed and rehydrated. The section was heat-treated in a
microwave oven and rinsed in Tris buffer. After blocking with
normal goat serum, the sections were stained with appropriate
dilutions of anti–HO-1 rabbit antiserum (Affinity BioReagents
Inc., Golden, Colorado, USA) for 1 h at room temperature. After
washing the slides in Tris buffer, alkaline phosphatase–conju-
gated goat anti–rabbit antiserum (TAGO Inc., Burlingame, Cal-
ifornia, USA) was reacted for 30 min at room temperature. Alka-
line phosphatase activity was visualized using Fast Red TR salt
(Sigma Chemical Co., St. Louis, Missouri, USA) after further
washing of the slides in Tris buffer.
Immunoblotting of HO-1 and HO-2. PBMC or LCLs were sus-
pended in Roswell Park Memorial Institute medium (RPMI)-
1640 containing 10% FCS and antibiotics and cultured for 6 h
with cadmium chloride (10 m M). Control cultures were per-
formed with medium alone. PBMC (2 · 106) or LCLs (1 · 107)
were washed in PBS, and the cell pellets were treated with 10%
TCA for 10 min on ice. The cells were spun down and sus-
pended in 100 m l of lysis solution containing 9 M urea, 2% Tri-
ton X-100, and 10% 2-mercaptoethanol. The mixture was dis-
rupted by sonication and neutralized with 1M Tris solution.
The lysates (25 m l per lane) were applied without boiling to
5%–20% polyacrylamide gradient gels (ATTO, Tokyo, Japan),
and electrophoresis was carried out in SDS. The proteins were
blotted onto nitrocellulose filters using a HORIZBLOT appa-
ratus (ATTO). Blots were blocked in 5% skim milk in PBS for 1
h and reacted with rabbit anti–HO-1 or anti–HO-2 antiserum
(Affinity BioReagents Inc.) diluted at 1:1,000 in PBS–0.1%
Tween-20 (PBS-T) for 1 h. The membranes were washed and
further incubated with horseradish peroxidase–conjugated
donkey anti–rabbit antibody (Chemicon International Inc.,
Temecula, California, USA) at a 1:20,000 dilution in PBS-T for
1 h. Immunoblots were developed by using an ECL Western
blotting detection system (Amersham International, Amer-
sham, United Kingdom) (7).
Cytotoxicity assay. LCLs were used to evaluate the sensitivity
to stress-inducing agents. The viability of all these cell lines or
clones was >90% before the culture, as determined by the try-
pan blue dye exclusion test. Cells were suspended in RPMI-
1649 culture medium supplemented with 10% FBS, 25 mM
HEPES, 5 · 10–5 M 2-mercaptoethanol, 100 U/ml penicillin,
and 10 m g/ml gentamicin at 105/ml. The cell suspension was
plated in 48-well culture plates (Costar No. 3548, Corning-
Costar Corp., Cambridge, Massachusetts, USA) and was cul-
tured for 24 h in the presence of various concentrations of
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Figure 1
Plasma and peripheral blood smears. (a) Centrifuged peripheral venous blood from control (left) and patient (right). (b) Peripheral blood smear was
stained by May-Grünwald and Giemsa. Arrows indicate fragmented erythrocytes.
Table 1
Changes in supernatant heme concentration in LCL cultures
Heme concentration
Hours of culture Control Patient
m M m M
2 49.9 ± 1.8 49.1 ± 1.5
6 48.6 ± 1.8 48.3 ± 2.2
12 49.2 ± 2.8 48.8 ± 2.5
24 48.6 ± 2.3 48.6 ± 2.0
LCLs from control and patient were cultured for indicated time period with 50 mM
hemin. Supernatant heme concentration was measured at each time point by pyri-
dine-hemochromogen method. Data shown are the means ± SD of five separate
experiments. LCL, lymphoblastoid cell line.
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hemin (Sigma Chemical Co.). Cell viability was analyzed by
flow cytometry after the culture. Dead cells were detected by
decreased forward light scatter, high annexin-V binding and
uptake of propidium iodide (8). Briefly, washed cells were
resuspended in annexin-V binding buffer, and FITC-conju-
gated annexin-V (Bender MedSystems, Vienna, Austria) was
added to the cell suspension at 1:500 dilution. Cells were react-
ed for 15 min in the dark and diluted 1:10 with the binding
buffer. Propidium iodide was added at 2 m g/ml to the cell sus-
pension before the analysis. Cell size, annexin-V binding, and
propidium iodide uptake were evaluated by an Ortho Cytoron
Absolute flow cytometer (Ortho Clinical Diagnostic Systems,
Tokyo, Japan). Cells with normal forward light scatter were
regarded as alive when annexin-V binding or propidium iodide
uptake was negative. Relative percentages of cell survival were
determined compared with the cells cultured with medium
alone. LCLs from the patient and the controls were cultured
with 50 m M hemin for various time periods, and the super-
natant was harvested at each time point.
Measurement of heme concentration. Serum or supernatant heme
concentration was measured by the pyridine-hemochromogen
method as described previously (9).
Analysis of HO-1 mRNAs. RNA was isolated with a standard acid
guanidinium phenol chloroform method from the patient, his
parents, and control LCLs cultured with 10 m M of cadmium
chloride for 6 h. Reverse transcription was performed with ran-
dom hexamer primer (Takara Shuzo Co., Tokyo, Japan) and
RAV-2 reverse transcriptase (Takara Shuzo Co.). PCR amplifi-
cation of the entire open reading frame of the HO-1 gene was
performed with primers HO-1 5N sense (5 ¢ -CTCCCCTC-
GAGCGTCCTC-3 ¢ ) and HO-1 3N antisense (5 ¢ -CCTTCAGT-
GCCC ACG GTAA-3¢ ). The PCR conditions were 95°C for 30 s,
55°C for 30 s, and 72°C for 90 s, for 35 cycles. After agarose gel
electrophoresis and ethidium bromide staining, each band was
cut out from the gel, and the PCR products were collected by the
standard electroelution method. Samples were sequenced with
the ABI Prism Dye Terminator sequencing kit (Perkin-Elmer
Applied Biosystems Foster City, California, USA) according to
the manufacturer’s instructions.
DNA extraction and paternal mutation–specific PCR. Genomic
DNA was extracted from the patient, his parents, and control
peripheral blood leukocytes according to the standard tech-
niques. PCR specific for the paternal mutation was performed
on genomic DNA with primers HO-1 del5 (5 ¢ -GCCCTGG
AGGAGGAGATTG-3 ¢ ) and HO-1 del3 (5 ¢ -GCGCTGCAT
GGCTGGTGTA-3 ¢ ) for 35 cycles at 95°C for 30 s, 58°C for 30
s, and 72°C for 30 s. For the DNA control, HO-1 3 (5 ¢ -
GGCTGGTGTGTAGGGGATG-3 ¢ ) was used instead of HO-1
del3 in combination with HO-1 del5, and PCR was performed
under the same conditions.
Results
Plasma and peripheral blood smears. The patient’s plasma,
centrifuged immediately after venipuncture, contained
large amounts of lipid in the upper layer. The plasma was
a dark maroon color and extremely turbid. Hematocrit
was always low (Fig. 1a). May-Grünwald and Giemsa
staining of the peripheral blood smear revealed abundant
fragmented or dysmorphic, bizarre-shaped erythrocytes
(Fig. 1b, arrows). Erythroblasts and Howell-Jolly bodies
were occasionally seen, and platelets were numerous.
Microscopic examination of renal biopsy specimen. Mild
mesangial proliferation and thickening of the capillary
loop were observed within the glomeruli. Scattered lym-
phocyte infiltration was also seen (Fig. 2a). By transmis-
sion electron microscopy, endothelial swelling and
detachment were prominent throughout the glomerular
capillary (Fig. 2b, arrow). An unidentifiable material was
deposited between the detached endothelium and
glomerular basement membrane (Fig. 2b, asterisk). A nor-
mal glomerular capillary is shown in Fig. 2c.
Iron staining of paraffin-embedded specimens. Iron stain-
ing was performed by a standard Prussian-blue stain-
Table 2
Comparison of findings between human HO-1 deficiency and HO-1 tar-
geted mouse
Findings Human Mouse
Intrauterine death Stillbirth, abortion 20% birth rate
Growth failure + +
Anemia + +
Fragmentation + ?
Iron binding capacity Increased Increased
Ferritin Elevated Elevated
Iron deposition + +
Hepatomegaly + +
Splenomegaly Asplenia +
Lymph node swelling + +
Leukocytosis + +
Thrombocytosis + ?
Coagulation abnormality + ?




Pathology of renal glomerular loop. (a) Hematoxylin and eosin staining
of the renal glomeruli. (b) Electron microscopy of glomerular capillary
of the patient. Arrow indicates the detached endothelium and asterisk
indicates subendothelial deposit. (c) Electron microscopy of control
glomerular capillary.
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ing method. Both kidney (Fig. 3a) and liver (Fig. 3b) sec-
tions contained multiple foci of iron deposition. Prox-
imal tubules were the major site of iron deposition
within the kidney. Iron deposition was very rare within
the glomeruli (Fig. 3a, asterisk). Both hepatic parenchy-
mal and Kupffer cells contained ferric iron.
Immunohistochemistry of HO-1–producing cells. Immuno-
histochemistry of paraffin-embedded liver sections is
shown in Fig. 4. Intense HO-1 staining was detected with-
in Kupffer cells of the control liver (Fig. 4a, arrow).
Parenchymal cells, however, did not produce HO-1. In
contrast, no HO-1 staining was detected in parenchymals
or Kupffer cells of the patient’s liver (Fig. 4b, arrow).
HO production by PBMC and LCL. PBMC, either from
the patient or three controls, did not produce HO-1
when they were cultured alone (Fig. 5a, lanes 1, 3, 5, and
7). PBMC from the patient did not produce any
detectable HO-1 after cadmium stimulation (Fig. 5a,
lane 2). In contrast, significant levels of HO-1 were
induced by cadmium within PBMC from the controls
(Fig. 5a, lanes 4, 6, and 8). Control LCL produced both
HO-1 and HO-2 after cadmium stimulation (Fig. 5b,
lane 1). LCLs from the father (Fig. 5b, lane 3) and the
mother (Fig. 5b, lane 4) also produced comparable lev-
els of HO-1 and HO-2. LCL from the patient, however,
produced only HO-2 and no detectable HO-1, even
after cadmium stimulation (Fig. 5b, lane 2). Different
stimulations, including sodium arsenite or hemin did
not induce HO-1 production by the patient’s LCL,
either (data not shown).
Cytotoxicity analysis. The sensitivity of the patient cell
lines to oxidative injury was tested by a cytotoxicity
analysis. Five different clones from patient LCL and
LCLs from five normal controls were selected for analy-
sis. Hemin, a substrate of HO-1, at different concen-
trations did not show any cytotoxicity against control
LCLs even after 24 hours of culture (Fig. 6, open circles).
Marked cell death was induced in the patient culture
after 24 hours (Fig. 6, closed circles). More than 60% of
the cells were dead at 50 m M of hemin, and the survival
rate declined dose-dependently. Kinetic study revealed
that patient LCL started to die after only 12 hours of
culture (data not shown).
Heme concentration in culture supernatant. In both con-
trol and patient cultures, heme concentrations in the
supernatant did not decrease significantly during 24
hours of culture (Table 1).
Mutational analysis of HO-1 gene. Structural organization
of HO-1 cDNA and construction of primers are shown
in Fig. 7. Reverse transcriptase-PCR for HO-1 mRNA was
performed using the primers as described in Methods.
Although the control expressed HO-1 mRNA of single
size (Fig. 8a, lane 1), both the patient and mother
expressed HO-1 mRNA of two different sizes (lane 2 and
lane 4, respectively). Cells from the father expressed a sin-
gle band of mRNA (lane 3). In the patient, the smaller
size was predominant, and only a minor fraction
revealed a near normal size. Direct sequencing of each
Figure 3
Iron staining of the kidney and liver. Paraffin-embedded specimens of the
kidney and liver were stained for iron. (a) Kidney. · 200. (b) Liver. · 200.
Asterisk indicates a glomerulus.
Figure 4
Immunohistochemical staining of HO-1 in the liver. Paraffin-embedded
specimen of the liver was stained with anti–HO-1 antiserum. (a) Control.
(b) Patient. Arrows indicate Kupffer cells. HO-1, heme oxygenase-1.
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band was performed. The larger, or paternal, band
showed a two-nucleotide deletion within exon3 (Fig. 8b).
Sequencing of the smaller, or maternal, band revealed a
complete loss of exon2 (Fig. 8c). Mutation-specific PCR
to detect the two-nucleotide deletion within exon3 was
performed using DNA preparations from the control
(Fig. 8d, lane 1), patient (lane 2), father (lane 3), and
mother (lane 4). The specific mutation was detected only
in the patient and father. Control PCR product was
detected similarly in each sample (Fig. 8e).
Discussion
HO-1 is a stress-induced isoform of heme oxygenases and
is not produced constitutively at a significant level (1, 2,
10). HO-1 is induced rapidly after oxidative stress and is
thought to act as a potent endogenous factor for the res-
olution of stress-induced inflammatory injury (11–14).
The detection of this particular isoform can, therefore, be
used as an indicator of oxidative injury in a particular tis-
sue, and modulation of the enzyme levels may alter the
antioxidative state of living organisms (15). Inhibition of
HO-1 activity may result in extreme vulnerability of an
individual to common stressful stimuli, including infec-
tions and environmental toxic substances (5). A cascade
of inflammatory reactions and vascular endothelial dam-
age may rapidly result, and various complications may
follow with sustained oxidative injury. However, no such
human disease with low or absent HO-1 activity has been
reported to date. In this regard, it is intriguing that Poss
and Tonegawa (16) recently reported on HO-1–targeted
mice, showing that they lack the ability to reuse iron and
are characterized by progressive anemia, tissue iron dep-
osition, chronic inflammation, and delayed growth. Fur-
thermore, these mice are extremely sensitive to oxidative
injury and are prone to death with lipopolysaccharide
(LPS) administration (17). Table 2 shows the summary of
characteristics of the HO-1–targeted mice in comparison
with those of our patient.
This study represents the first reported case of human
HO-1 deficiency. It is recently reported that Kupffer cells
are the major source of HO-1 production in rat liver (18).
Immunohistochemical study in this report also shows
that HO-1 is primarily produced by Kupffer cells in the
liver. Absence of HO-1 staining in the patient clearly
indicates that he lacks HO-1 production in vivo upon
physiological stresses. PBMC from the patient did not
produce HO-1 even when they were stimulated by an
optimum concentration of cadmium, further indicating
that the patient has a genetic abnormality in HO-1 gene.
Lack of HO-1 production by LCLs from the patient
argues against the possibility that HO-1 production by
Kupffer cells or PBMC was secondarily downregulated
by the sustained inflammatory state in this patient. In
addition, mutations were detected in both alleles of HO-
1 gene, further confirming that the HO-1 defect in the
patient is the primary abnormality.
Hemoglobin and its metabolites are known to be
potent inducers of HO-1 (13, 14, 19). It was clearly
shown by the cytotoxicity assay that HO-1 provides
efficient protection against certain oxidative stress,
such as hemin. HO-2, which is expressed normally and
constitutively within the patient’s cells, does not pro-
vide protection against hemin-induced cell injury. Fur-
thermore, the cell protection provided by HO-1 is not
simply through the degradation of heme added to the
culture, because heme was added in excess in the form
of hemin, and there was no significant decrease in the
heme concentration even in the culture of control
LCLs. The precise mechanism of hemin-induced death
of HO-1–deficient cells is currently being studied
extensively. These in vitro studies and the clinical symp-
toms presented by the patient demonstrate the critical
importance of HO-1, rather than HO-2, in iron metab-
olism and cell protection from oxidative damage.
Figure 5
Immunoblotting of HO-1 induced in cadmium-stimulated cells. (a)
PBMC from patient (lanes 1 and 2) and control 1 (lanes 3 and 4). Con-
trol 2 (lanes 5 and 6), and control 3 (lanes 7 and 8) were cultured alone
(lanes 1, 3, 5, and 7) or with cadmium (lanes 2, 4, 6, and 8). Lysate sam-
ples were prepared as shown in Methods. Blotted membrane was react-
ed simultaneously with anti–HO-1 antiserum and anti–HO-2 antiserum,
followed by the reaction with HRP-conjugated anti–rabbit IgG. (b) LCLs
from patient, parents, and control were cultured with cadmium and
treated similarly. Lane 1, control; lane 2, patient; lane 3, father; and lane
4, mother. HRP, horseradish peroxidase; LCL, lymphoblastoid cell line,
PBMC, peripheral blood mononuclear cells.
Figure 6
Cytotoxicity assay. LCLs from patient (closed circles) and control (open cir-
cles) were cultured for 24 h with different concentrations of hemin. Dead
or apoptotic cells were identified by lowered forward light scatter and
high annexin-V binding using a flow cytometer. Percent survival was deter-
mined compared with cells cultured with medium. Each datum repre-
sents the mean ± SD of five independent experiments. *P < 0.001.
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Many of the clinical features and laboratory findings
are compatible with those found in HO-1–targeted
mice, as shown in Table 2. It is not clear, however, if the
spectrum of clinical findings and laboratory data
observed in this patient can be explained solely by the
lack of HO-1. Certainly, asplenia makes some contri-
bution to the modulation of the patient’s condition,
either by prolonging the intravascular survival of dam-
aged cells and therefore augmenting the heme-medi-
ated oxidative stress, or by minimizing the red cell
destruction and preventing the progression of anemia.
The mechanism of hyperlipidemia, with high choles-
terol and triglyceride levels, is not clear. Prolonged cor-
ticosteroid therapy alone may explain the levels seen in
this patient. Bilirubin is a known antioxidant (20), and
it also acts as a scavenger for degraded LDL cholesterol
(21–24). Impaired bilirubin production in this patient
might also be responsible for the abnormally elevated
serum cholesterol. Furthermore, a high LDL choles-
terol level itself, coupled with free heme, may acceler-
ate the oxidative injury of the vascular endothelium
(25). High thrombomodulin concentration indicates
that the patient’s endothelium suffers constant injury
(26, 27). Electron microscopic study of the patient’s
kidney shows peculiar detachment of the endothelium
within the glomeruli. These changes may lead to the
constant destruction of erythrocytes and platelets.
Fragmented, exhausted erythrocytes and platelets may
persist within the circulation for a long time in the
absence of a spleen, and they may in turn damage the
endothelium and act as potent procoagulants (28).
Iron deposition was detected within renal proximal
tubular epithelium, hepatic parenchymal cells, and
Kupffer cells in HO-1–targeted mice. Our patient
showed similar iron deposition, and the finding is
again compatible with the mouse model. Cellular infil-
tration in the liver or kidney was much less impressive
in the patient samples than the findings reported in
HO-1–targeted mice. The age of the patient and histo-
ry of stress exposures may alter the course of the illness
and pathological findings significantly. Although the
existence of renal damage in HO-1–targeted mice has
not been described, heme and its derivatives are known
to cause renal tubular damage, and a recent report
indicated that HO-1 plays an important role in pro-
tecting against epithelial injury of renal tubules (29).
HO-1 defect is certainly responsible for the renal tubu-
lar injury and subsequent proteinuria and hematuria
seen in this patient.
Although there is no positive family history or con-
sanguinity of the parents, abnormality of HO-1 gene
was confirmed by the mutational analysis of both alle-
les of HO-1 gene. Milder cases, with unexplained chron-
ic inflammation, may be found in the future if careful
analysis of HO-1 gene is performed. Our patient may
represent an extreme end and a prototype of HO-1 defi-
ciency that has a wide spectrum of clinical presenta-
tions. Analysis of the complicated features of the patient
may lead to a further understanding of the key roles
played by HO-1 in vivo.
Figure 7
Structural organization of HO-1 gene and construction of PCR primers
for mutational analysis.
Figure 8
Mutational analysis of HO-1 gene. (a)
Reverse transcriptase-PCR for HO-1
mRNA. M denotes molecular weight
marker. Lane 1, control; lane 2, patient;
lane 3, father; and lane 4, mother. (b)
Sequence analysis of paternal allele and
normal control allele. (c) Sequence
analysis of maternal allele and normal
control allele. (d) Mutation- specific
PCR of genomic DNA. Data from con-
trol (lane 1), patient (lane 2), father
(lane 3), and mother (lane 4) are shown.
(e) Control PCR.
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